abstract |
The present application relates to anti-PD-L1 antibodies or their antigen binding fragments, nucleic acids encoding them, their therapeutic compositions and their use to improve the function of T cells to regulate upward cell-mediated immune responses and to the treatment of dysfunctional T-cell disorders, such as tumor immunity, for the treatment of cancer. |